About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Legislative Tracking Tools
Daily Archives: August 2, 2008
HIV Incidence Higher Than Previously Known: Waxman Blasts Administration
There will be a great deal of news this week about the HIV epidemic given the fact that the XVII International AIDS Conference (IAC) will be starting this weekend in Mexico City. Therefore, you may notice more postings about this … Continue reading
Posted in Current Affairs Comments Off on HIV Incidence Higher Than Previously Known: Waxman Blasts Administration
BMS Moves to Acquire ImClone
Ok, this is a few days late, but like I said, I was really busy this week. At any rate, here is the complete reprint of the press release from BMS. Bristol-Myers Squibb Proposes to Acquire ImClone Systems for $60.00 … Continue reading
Posted in Business/Industry News Comments Off on BMS Moves to Acquire ImClone